1. Effectiveness and safety of rivaroxaban versus warfarin for treatment of cancer-associated venous thrombosis. Issue 164 (April 2018) Authors: Coleman, C.I.; Bunz, T.J.; Kohn, C.G.; Beyer-Westendorf, J. Journal: Thrombosis research Issue: Issue 164(2018)Supplement 1 Page Start: S203 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OC-16: Comparison of VTE recurrence, bleeding-related hospitalization and all-cause mortality in patients with active cancer in two patient populations, based upon cancer types considered to have high and low risks of bleeding, receiving DOACs or LMWH: The OSCAR UK Study. Issue 213 (May 2022) Authors: Cohen, A.T.; Wallenhorst, C.; Ay, C.; Schaefer, B.; Abdelgawwad, K.; Psaroudakis, G.; Brobert, G.; Coleman, C.I.; Ekbom, A.; Lee, A.Y.Y.; Khorana, A.A.; Becattini, C.; Carrier, M.; Rivera, M.; Martinez, C. Journal: Thrombosis research Issue: Issue 213(2022)Supplement 2 Page Start: S9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Systematic review and meta-analysis of real-world studies evaluating rivaroxaban for cancer-associated venous thrombosis. Issue 164 (April 2018) Authors: Martinez, B.K.; Sheth, J.; Patel, N.; Baker, W.L.; Coleman, C.I. Journal: Thrombosis research Issue: Issue 164(2018)Supplement 1 Page Start: S205 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗